增用司来帕格片对肺动脉高压患儿的疗效及安全性分析

Efficacy and safety analysis of additional use of Selexipag tablets in children with pulmonary arterial hypertension

目的研究增用司来帕格片对肺动脉高压(PAH)患儿的疗效及安全性方法选取82例自2015年1月起直至2018年12月我院收治的PAH患儿进行研究,以随机抽取原则,将其等分成试验组及参照组。参照组予以综合治疗以及米力农注射液治疗,试验组则于参照组的基础上增用司来帕格片治疗。分别对比两组治疗前后PAP水平,机械通气时间、住院时间,治疗前后两组心功能指标水平,死亡率。结果治疗后试验组及参照组的PAP水平分别为(42.39±4.11)mmHg、(49.23±4.80)mmHg,相比治疗前较低,且试验组相比参照组较低(均P<0.05)。试验组机械通气时间、住院时间分别为(6.12±1.23)d、(15.02±1.88)d,相比参照组的(7.66±2.05)d、(20.57±3.07)d较低(均P<0.05)。治疗前后试验组与参照组在各项心功能指标水平方面比较均不明显(均P>0.05)。试验组死亡率相比参照组较低(P<0.05)。结论增用司来帕格片可显著提高PAH患儿的临床疗效,同时有效缩短患儿的机械通气时间,促进其早日康复,且可明显降低患儿死亡率,值得临床推广应用。

Objective To study and analyze the efficacy and safety of additional use of Selexipag tablets in children with pulmonary arterial hypertension(PAH).Methods 82 children with PAH admitted to our hospital from January 2015 to December 2018 were selected for study,and they were randomly divided into the experimental group and the reference group.The control group was treated with comprehensive therapy and milinone injection,while the experimental group was treated with Selexipag tablets on the basis of the control group.Their PAP levels,duration of mechanical ventilation and hospital stay,cardiac function indexes and mortality before and after treatment were compared between the two groups.Results After treatment,the PAP level of the experimental group and the control group was(42.39±4.11)mmHg and(49.23±4.80)mmHg respectively,which were lower than those before treatment,and the PAP level of the experimental group was lower than those of the control group(all P<0.05).The duration of mechanical ventilation and hospital stay in the experimental group were(6.12±1.23)d and(15.02±1.88)d respectively,which were lower than those in the control group[(7.66±2.05)d and(20.57±3.07)d(all P<0.05)].Before and after treatment,there was no significant difference in the level of various cardiac function indicators between the two groups(all P>0.05).The mortality of the experimental group was lower than that of the control group(P<0.05).Conclusion The additional use of Selexipag tablet can significantly improve the clinical efficacy of PAH in children,effectively shorten the time of mechanical ventilation,promote their early recovery,and significantly reduce the mortality of children,which is worthy of widely clinical application.